Understanding the role of 14-3-3Ƞ protein in rheumatoid arthritis: from molecular dysregulation to therapeutic Redirection.

Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation in the synovial joints, resulting in joint damage and systemic complications. The 14-3-3η protein, a member of the 14-3-3 family of regulatory proteins, has shown promise as a biomarker and a potential therapeutic target for treating RA. High levels of 14-3-3η protein have been consistently detected in the synovial fluid and blood serum of RA patients, showing a relationship with disease severity and joint deterioration. Functionally, 14-3-3η protein interacts with various intracellular signaling pathways that control immune responses, apoptosis, and cell survival. It enhances the production of pro-inflammatory cytokines, which contribute to joint swelling and bone loss in RA. The clinical implications of 14-3-3η protein are substantial. Furthermore, targeting the 14-3-3η protein and its associated pathways, such as MAPK/ERK, SAPK/JNK, and JAK-STAT, offers a new therapeutic strategy for reducing inflammation and preventing joint damage. Recent preclinical research has shown that drugs that inhibit 14-3-3η protein expression levels reduce synovial inflammation and bone loss, highlighting its potential as a disease-modifying intervention in RA.